Effects of renal denervation on end organ damage in hypertensive patients

European Journal of Preventive Cardiology

Volumn 22, Issue 5, 2015, Pages 558-567

  Verloop, Willemien L ^a   Vink, Eva E ^a   Spiering, Wilko ^a   Blankestijn, Peter J ^a   Doevendans, Pieter A ^a   Bots, Michiel L ^a   Vonken, Evert Jan ^a   Voskuil, Michiel ^a   Leiner, Tim ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

albuminuria; arterial stiffness; end organ damage; left ventricular hypertrophy; Renal denervation

Indexed keywords

ALBUMIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NARCOTIC AGENT; RENIN INHIBITOR;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTERIAL STIFFNESS; ARTICLE; AUGMENTATION INDEX; BLOOD PRESSURE MEASUREMENT; BODY SURFACE; CARDIAC PATIENT; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL TRIAL; COHORT ANALYSIS; END ORGAN DAMAGE; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE MASS; HUMAN; INFORMED CONSENT; KIDNEY DENERVATION; KIDNEY INJURY; MAJOR CLINICAL STUDY; MALE; PAIN; PATIENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULSE WAVE; RESISTANT HYPERTENSION; SPHYGMOMANOMETER; STANDARDIZATION; URINALYSIS; URINARY EXCRETION; ADRENERGIC SYSTEM; ALBUMINURIA; ANATOMY AND HISTOLOGY; BLOOD PRESSURE; DENERVATION; HEART VENTRICLE; HYPERTENSION; INNERVATION; KIDNEY; KIDNEY CIRCULATION; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; RADIOGRAPHY; SURGERY; SYMPATHECTOMY; URINE;

AGED; ALBUMINURIA; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; DENERVATION; FEMALE; HEART VENTRICLES; HUMANS; HYPERTENSION; KIDNEY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULSE WAVE ANALYSIS; RENAL CIRCULATION; SYMPATHECTOMY; SYMPATHETIC NERVOUS SYSTEM; VASCULAR STIFFNESS;

EID: 84927603655     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/2047487314556003     Document Type: Article

References (35)

1. Yoon SS, Burt V, Louis T, et al. Hypertension among adults in the United States, 2009-2010. NCHS Data Brief 2012; 107: 1-8.
2. Global Health Observatory G. Raised blood pressure. Situation and Trends 2013. Available at: http://www.who.int/gho/ncd/risk-factors/blood-pressure-prevalence-text/en/.
3. Grassi G, Seravalle G, Dell'Oro R, et al. Sympathetic mechanisms, organ damage, and antihypertensive treatment. Curr Hypertens Rep. 2011 ; 13: 303-308
4. Vernooij JW, van der Graaf Y, Nathoe HM, et al. Hypertensive target organ damage and the risk for vascular events and all-cause mortality in patients with vascular disease. J Hypertens. 2013 ; 31: 492-499
5. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: Diagnosis, evaluation, and treatment: A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008 ; 117: e510-e526
6. Muiesan ML, Salvetti M, Rizzoni D, et al. Resistant hypertension and target organ damage. Hypertens Res. 2013 ; 36: 485-491
7. Grassi G. Sympathetic neural activity in hypertension and related diseases. Am J Hypertens. 2010 ; 23: 1052-1060
8. Krum H, Schlaich MP, Sobotka PA, et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: Final 3-year report of the Symplicity HTN-1 study. Lancet 2014; 383: 622-629.
9. Esler MD, Bohm M, Sievert H, et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 Month results from the SYMPLICITY HTN-2 randomized clinical trial. Eur Heart J 2014; 35: 1752-1759.
10. Bhatt DL, Kandzari DE, O'Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014; 370: 1393-1401.
11. Verloop WL, Vink EE, Voskuil M, et al. Eligibility for percutaneous renal denervation: The importance of a systematic screening. J Hypertens. 2013 ; 31: 1662-1668
12. Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: Blood pressure measurement in humans: A statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation. 2005 ; 111: 697-716
13. Jaspers K, Freling HG, van Wijk K, et al. Improving the reproducibility of MR-derived left ventricular volume and function measurements with a semi-automatic threshold-based segmentation algorithm. Int J Cardiovasc Imaging. 2013 ; 29: 617-623
14. van Dijk SC, Smulders YM, Enneman AW, et al. Homocysteine level is associated with aortic stiffness in elderly: Cross-sectional results from the B-PROOF study. J Hypertens. 2013 ; 31: 952-959
15. Stevens PE, Levin A and Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: Synopsis of the kidney disease: Improving global outcomes 2012 clinical practice guideline. Ann Intern Med 2013; 158: 825-830.
16. Schlaich MP, Sobotka PA, Krum H, et al. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009; 361: 932-934.
17. Moons KG, Royston P, Vergouwe Y, et al. Prognosis and prognostic research: What, why, and how? Br Med J 2009; 338: b375.
18. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: A meta-analysis. Lancet. 2001 ; 358: 1305-1315
19. Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: A multicentre safety and proof-of-principle cohort study. Lancet 2009; 373: 1275-81.
20. Esler MD, Krum H, Sobotka PA, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): A randomised controlled trial. Lancet 2010; 376: 1903-1909.
21. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013 ; 31: 1281-1357
22. Siddiqi L, Prakken NH, Velthuis BK, et al. Sympathetic activity in chronic kidney disease patients is related to left ventricular mass despite antihypertensive treatment. Nephrol Dial Transplant. 2010 ; 25: 3272-3277
23. Brandt MC, Mahfoud F, Reda S, et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol. 2012 ; 59: 901-909
24. Schirmer SH, Sayed MM, Reil JC, et al. Improvements of left-ventricular hypertrophy and diastolic function following renal denervation-effects beyond blood pressure and heart rate reduction. J Am Coll Cardiol 2013; 63: 1916-1923.
25. Armstrong AC, Gidding S, Gjesdal O, et al. LV mass assessed by echocardiography and CMR, cardiovascular outcomes, and medical practice. JACC Cardiovasc Imaging. 2012 ; 5: 837-848
26. Brandt MC, Reda S, Mahfoud F, et al. Effects of renal sympathetic denervation on arterial stiffness and central hemodynamics in patients with resistant hypertension. J Am Coll Cardiol. 2012 ; 60: 1956-1965
27. Ott C, Janka R, Schmid A, et al. Vascular and renal hemodynamic changes after renal denervation. Clin J Am Soc Nephrol. 2013 ; 8: 1195-1201
28. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: Principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113: 1213-1225.
29. Monster TB, Janssen WM, de Jong PE, et al. The impact of antihypertensive drug groups on urinary albumin excretion in a non-diabetic population. Br J Clin Pharmacol 2002; 53: 31-6.
30. Fogari R, Mugellini A, Zoppi A, et al. Effect of successful hypertension control by manidipine or lisinopril on albuminuria and left ventricular mass in diabetic hypertensive patients with microalbuminuria. Eur J Clin Pharmacol. 2005 ; 61: 483-490
31. Dalla Vestra M, Pozza G, Mosca A, et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina). Diabetes Nutr Metab 2004; 17: 259-266.
32. Stehouwer CD, Nauta JJ, Zeldenrust GC, et al. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 1992; 340: 319-323.
33. Grothues F, Smith GC, Moon JC, et al. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol 2002; 90: 29-34.
34. Blankestijn PJ, Alings M, Voskuil M, et al. The complexity after simplicity: How to proceed with renal denervation in hypertension? Eur J Prev Cardiol. Epub ahead of print 9 June 2014. DOI: 2047487314538859.
35. Miller M, Gangireddy S, Dukkipati S, et al. Renal sympathetic denervation using an electroanatomical mapping system. J Am Coll Cardiol 2014; 63: 1697.